Kodiak Sciences (NASDAQ:KOD – Get Free Report) announced its earnings results on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06, Zacks reports.
Kodiak Sciences Stock Performance
Shares of NASDAQ KOD opened at $2.91 on Friday. The stock has a market capitalization of $153.14 million, a PE ratio of -0.80 and a beta of 2.26. Kodiak Sciences has a 52 week low of $2.19 and a 52 week high of $11.60. The stock has a 50 day moving average price of $4.85 and a 200 day moving average price of $5.40.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, December 9th.
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
See Also
- Five stocks we like better than Kodiak Sciences
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 03/24 – 03/28
- What is the Nikkei 225 index?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
